Immunotherapy shows promise for rare adrenal cancer
NCT ID NCT02673333
First seen Apr 14, 2026 · Last updated May 07, 2026 · Updated 4 times
Summary
This study tests pembrolizumab, an immunotherapy drug, in 39 people with advanced adrenocortical carcinoma that cannot be removed by surgery. The goal is to see if the drug can shrink or control the cancer. Participants receive the drug for up to 24 months, and the study measures how many have their tumors shrink significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENOCORTICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
University of Michigan (Data or Specimen Analysis Only)
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.